AR064459A1 - Derivados de sulfonamida - Google Patents
Derivados de sulfonamidaInfo
- Publication number
- AR064459A1 AR064459A1 ARP070105736A ARP070105736A AR064459A1 AR 064459 A1 AR064459 A1 AR 064459A1 AR P070105736 A ARP070105736 A AR P070105736A AR P070105736 A ARP070105736 A AR P070105736A AR 064459 A1 AR064459 A1 AR 064459A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- alkyl
- alkoxy
- hydroxy
- fluor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos, para tratar hiperglucemia y diabetes. Reivindicacion 1: Compuestos de la formula (1) en la que X es -NHC(O)- o -C(O)NH-; Y es -C(R4R5)-, -C(R4R5)C(R6R7)-, - C(R4R5)C(R6R7)C(R8R9)-, -C(R4R5)C(R6R7)C(R8R9)C(R10R11- o -CR4=CR6-; R1 es arilo o heteroarilo, dicho arilo o heteroarilo está sustituido por -C(R12R13) [C(R14R15)]nC(O)OR16 y dicho arilo o heteroarilo está además opcionalmente sustituido por 1 o 2 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, hidroxi, halogeno, alcoxi inferior, fluor-alquilo inferior y fluor-alcoxi inferior; R2 es hidrogeno, alquilo inferior, hidroxi, halogeno, alcoxi inferior, fluor- alquilo inferior o fluor-alcoxi inferior; R3 es arilo, que está opcionalmente sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por halogeno, ciano, hidroxi, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, (alquilo inferior)-C(O), (alquilo inferior)-C(O)-NH, (alquilo inferior)-C(O)-N(alquilo inferior), (alquilo inferior)-S(O)2, NH2-S(O)2, N(H,alquilo inferior)-S(O)2, N(alquilo inferior)2-S(O)2, NH2-C(O), N(H,alquilo inferior)- C(O), N(alquilo interior)2-C(O) y alcoxi interior-C(O), en los que el alquilo interior está opcionalmente sustituido por hidroxi, alcoxi inferior, NH2, N(H,alquilo interior) o N(alquilo interior)2; R4, R5, R6, R7, R8, R9, R10 y R11 con independencia entre sí son hidrogeno, halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo interior, fluor-alcoxi interior, hidroxi o hidroxi-alquilo inferior; R12, R13, R14 y R15 con independencia entre sí son hidrogeno, halogeno, alquilo interior, alcoxi interior, fluoralquilo inferior, fluor-alcoxi interior, hidroxi, hidroxi-alquilo inferior; o R13 es H y R12 es -(CH2)1-3- y forma un puente con el arilo o heteroarilo, al que está unido el -C(R12R13) [C(R14R15))]2-C(O)OR1; R16 es hidrogeno o alquilo inferior; n es el numero 0 o 1; y sus sales y ésteres farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126920 | 2006-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064459A1 true AR064459A1 (es) | 2009-04-01 |
Family
ID=39273549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105736A AR064459A1 (es) | 2006-12-21 | 2007-12-19 | Derivados de sulfonamida |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7799933B2 (es) |
| EP (1) | EP2097373B1 (es) |
| JP (1) | JP5089707B2 (es) |
| KR (1) | KR101139211B1 (es) |
| CN (1) | CN101583597B (es) |
| AR (1) | AR064459A1 (es) |
| AT (1) | ATE477240T1 (es) |
| AU (1) | AU2007336364B2 (es) |
| BR (1) | BRPI0720524A2 (es) |
| CA (1) | CA2672761A1 (es) |
| CL (1) | CL2007003697A1 (es) |
| DE (1) | DE602007008467D1 (es) |
| ES (1) | ES2348270T3 (es) |
| MX (1) | MX2009006598A (es) |
| PE (1) | PE20081485A1 (es) |
| TW (1) | TW200833324A (es) |
| WO (1) | WO2008074692A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017827A1 (en) * | 2008-08-14 | 2010-02-18 | European Molecular Biology Laboratory | 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| EP2638014B1 (en) | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6242868B2 (ja) | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物 |
| RU2014149136A (ru) * | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| US9266827B2 (en) * | 2012-05-08 | 2016-02-23 | Merck Sharp & Dohme Corp. | Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| EP3110429A4 (en) | 2014-02-27 | 2018-02-21 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| JP6728061B2 (ja) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 |
| US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016344115A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
| JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| CN110511182B (zh) * | 2019-09-03 | 2023-01-17 | 上海昕凯医药科技有限公司 | 一种连续流反应合成7-硝基-1,2,3,4-四氢喹啉的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| ATE466838T1 (de) | 2005-06-06 | 2010-05-15 | Hoffmann La Roche | Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer |
| WO2007031429A1 (en) | 2005-09-15 | 2007-03-22 | F. Hoffmann-La Roche Ag | Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase |
-
2007
- 2007-12-06 US US11/951,426 patent/US7799933B2/en not_active Expired - Fee Related
- 2007-12-11 AU AU2007336364A patent/AU2007336364B2/en not_active Ceased
- 2007-12-11 KR KR1020097012803A patent/KR101139211B1/ko not_active IP Right Cessation
- 2007-12-11 ES ES07857385T patent/ES2348270T3/es active Active
- 2007-12-11 DE DE602007008467T patent/DE602007008467D1/de active Active
- 2007-12-11 EP EP07857385A patent/EP2097373B1/en not_active Not-in-force
- 2007-12-11 MX MX2009006598A patent/MX2009006598A/es active IP Right Grant
- 2007-12-11 BR BRPI0720524-4A patent/BRPI0720524A2/pt not_active IP Right Cessation
- 2007-12-11 JP JP2009541983A patent/JP5089707B2/ja not_active Expired - Fee Related
- 2007-12-11 CA CA002672761A patent/CA2672761A1/en not_active Abandoned
- 2007-12-11 WO PCT/EP2007/063696 patent/WO2008074692A1/en active Application Filing
- 2007-12-11 CN CN2007800471883A patent/CN101583597B/zh not_active Expired - Fee Related
- 2007-12-11 AT AT07857385T patent/ATE477240T1/de active
- 2007-12-14 PE PE2007001806A patent/PE20081485A1/es not_active Application Discontinuation
- 2007-12-18 TW TW096148490A patent/TW200833324A/zh unknown
- 2007-12-19 AR ARP070105736A patent/AR064459A1/es not_active Application Discontinuation
- 2007-12-19 CL CL200703697A patent/CL2007003697A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008074692A1 (en) | 2008-06-26 |
| AU2007336364B2 (en) | 2012-08-02 |
| MX2009006598A (es) | 2009-07-24 |
| EP2097373A1 (en) | 2009-09-09 |
| KR20090080567A (ko) | 2009-07-24 |
| US20080153805A1 (en) | 2008-06-26 |
| CA2672761A1 (en) | 2008-06-26 |
| CN101583597B (zh) | 2012-07-11 |
| BRPI0720524A2 (pt) | 2014-01-07 |
| TW200833324A (en) | 2008-08-16 |
| CL2007003697A1 (es) | 2008-07-04 |
| DE602007008467D1 (de) | 2010-09-23 |
| ES2348270T3 (es) | 2010-12-02 |
| ATE477240T1 (de) | 2010-08-15 |
| EP2097373B1 (en) | 2010-08-11 |
| CN101583597A (zh) | 2009-11-18 |
| KR101139211B1 (ko) | 2012-04-26 |
| AU2007336364A1 (en) | 2008-06-26 |
| PE20081485A1 (es) | 2008-10-18 |
| JP5089707B2 (ja) | 2012-12-05 |
| JP2010513376A (ja) | 2010-04-30 |
| US7799933B2 (en) | 2010-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064459A1 (es) | Derivados de sulfonamida | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| ES2491140T3 (es) | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación | |
| ES2515095T3 (es) | Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| TW200639158A (en) | New compounds with therapeutic effect | |
| ECSP088773A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| PE20081530A1 (es) | Nuevos compuestos 617 | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
| AR089182A1 (es) | Derivados de aminopirimidina como moduladores de lrrk2 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR055959A1 (es) | Derivados espiro para la modulacion de actividad de crth2 | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| PE20070550A1 (es) | Derivados de la 1-amino-ftalazina sustituida afines al receptor mch1 y su preparacion | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
| CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |